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Inhibitor-2 In Vivo Enhances Protein Phosphatase-1 Activity
and Suppresses Learning andMemory: Possible Implication
for the Progression of Tau Pathology
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The Netherlands
Review of Yang et al.
Learning andmemory are important cog-
nitive functions, vital to survival. Diseases
impairing these functions thus have huge
consequences for the normal functioning
of an individual. Illnesses associated with
dementia, such as Alzheimer’s disease
(AD), currently contribute significantly to
the worldwide disease burden, with an
estimated 47.5 million people living with
dementia in 2015 (World Health Organi-
zation, 2015). As this number is predicted
to double each year, it will bring extensive
personal and societal costs. Unfortu-
nately, the neurobiological mechanisms
underlying deficits associated with learn-
ing and memory are still not fully under-
stood. Studies addressing the molecular
and cellular underpinnings of normal
learning andmemorywill greatly improve
our understanding of memory-related
impairments and might point to much-
needed therapeutic interventions.
One biological process related to learn-
ing andmemory is proteinphosphorylation
and dephosphorylation. For example, pro-
tein phosphatase-1 (PP1) was found to
attenuate memory in a mouse model (Ge-
noux et al., 2002). PP1 is a major phospha-
tase of CREB (cAMP/calcium response
element-binding protein), which promotes
gene expression essential for memory for-
mation (Lonze and Ginty, 2002). It is thus
likely that thememory-constraining actions
of PP1 aremediated through inactivation of
CREB via dephosphorylation.
Based on in vitro studies, it was previ-
ously suspected that PP1 activity is atten-
uated by an endogenous inhibitor named
PP1 inhibitor-2 (I-2; Cohen, 1989). How-
ever, results byHou et al. (2013) suggested
that the in vivo function of I-2 might be
more complex thanmerely inhibiting PP1
activity, because I-2 knock-down led to
decreased, rather than increased, PP1 ac-
tivity in rat primary cortical neurons. A
follow-up study by the same group re-
vealed that in vivo I-2 indeed enhances
rather than suppresses PP1 activity (Yang
et al., 2015).
Yang et al. (2015) examined the effects
of heterozygous I-2 knock-out in mice
and shRNA-mediated knockdown of I-2
in rats. In homozygous I-2 knock-out
mice, I-2 was completely absent and these
animals died as embryos. Heterozygous
animals (I-2/) on the other hand, were
healthy and showed no abnormal pheno-
types. I-2 levels in the brains of these ani-
mals were 50% of those detected in
wild-type littermates (Yang et al., 2015).
I-2/ mice showed enhanced perfor-
mance compared with wild types in both
novel object recognition and contextual
fear conditioning tasks, suggesting that in
vivo, I-2 limits memory and learning
(Yang et al., 2015, their Fig. 1D,E). To
exclude the possibility that these effects
were due to unknown developmental
compensation, shRNA-mediated-knock-
down experiments were performed. The
same authors previously showed that such
knockdown decreased I-2 levels in cul-
tured cortical neurons (Hou et al., 2013).
However, whether the knockdown is
similarly efficient in vivo has not been
shown and data indicating the extent of
decreased I-2 expression in the experi-
mental animals is lacking. Nonetheless, a
significant positive effect on learning and
memory was observed in I-2 knockdown
rats in Morris water maze and contextual
fear conditioning tasks (Yang et al., 2015,
their Fig. 2). These behavioral results sug-
gest that I-2 acts endogenously as a nega-
tive regulator of memory function.
The observation that I-2 modulates
memory in the same direction as PP1 im-
plies that I-2 has a stimulatory rather than
an inhibitory function. In line with this,
Yang et al. (2015) found that phosphory-
lated CREB levels and CREB-mediated
gene expression were increased after I-2
reduction in both rats and mice (Yang et
al., 2015, their Fig. 3). Further support for
an enhancing effect of I-2 on PP1 in vivo is
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provided by the finding that PP1 activity
was decreased in brain lysates of I-2/
mice, whereas PP1 expression levels re-
mained unaffected (Yang et al., 2015, their
Fig. 4A,B). In short, I-2 emerges as a new
memory suppressor, potentially acting by
enhancing PP1 activity.
Although these findings strongly sug-
gest that I-2’s effects on learning and
memory task performance are mediated
via PP1, it remains possible that I-2 and
PP1 independently alter learning and
memory performance. To gain conclusive
evidence, a follow-up study should con-
tain a comparison between animals in
which PP1 or PP1 and I-2 are inhibited. If
the effects of I-2 are indeed mediated via
PP1, the additional inhibition of I-2
should not cause further effects on learn-
ing and memory performance.
Because of the involvement of PP1 and
I-2 in learning and memory processes,
both might also be implicated in AD,
given that this disease is associated with
cognitive decline. AD is a neurodegenera-
tive disorder characterized by two types of
pathophysiological hallmarks in the
brain, namely amyloid plaques and neu-
rofibrillary tangles (Iqbal et al., 2013).
Patients suffer from progressively im-
paired memory function, the severity of
which is best correlated with the presence
of neurofibrillary tangles (Riley et al.,
2002). These neurofibrillary tangles are
generated when tau proteins become ab-
normally (hyper)phosphorylated and oli-
gomerize into paired helical filaments,
which subsequently aggregate as tangles
(Iqbal et al., 2010). Although it is cur-
rently unknown whether I-2 interacts
with AD pathology, protein phosphatases
have been linked to AD. The activity of
PP1 and PP2A (protein phosphatase-2A)
is decreased in the brains of AD patients
(Gong et al., 1993). Additionally, it has
been demonstrated that both PP1 and
PP2a can dephosphorylate tau. Although
PP2A accounted for 71%of the regulation
of tau phosphorylation, PP1 also contrib-
uted 11% (Liu et al., 2005). Other protein
phosphatases were responsible for the
remaining 18%. Interestingly, PP1 was
more effective than PP2A in dephospho-
rylating tau at certain phosphorylation
sites (Liu et al., 2005). Therefore, it can be
speculated that PP1, together with PP2A,
might inhibit the development of AD pa-
thology by decreasing tau hyperphospho-
rylation and thus tangle formation. It is
possible that I-2 has similar inhibitory ef-
fects on tau hyperphosphorylation, as it
increases PP1 activity (Fig. 1), but no
studies have looked into this so far.
Further support for the inhibitory role
of protein phosphatases in AD pathology
is given by the observation that when
PP2A levels were selectively increased, less
tau hyperphosphorylation occurred in
transgenic mice expressing a human form
of tau (Zhang et al., 2014). Remarkably,
thesemice also exhibited enhanced cogni-
tive abilities, which possibly resulted from
the relieved tau pathology. Furthermore,
when PP1 and PP2A were both inacti-
vated in rats with the nonspecific inhibi-
tor calyculin A, tau hyperphosphorylation
increased and spatial memory was im-
paired temporarily (Sun et al., 2003).
Studies selectively probing the effect of
PP1 on tau hyperphosphorylation and
cognition are currently lacking due to ab-
sence of selective PP1 inhibitors, and thus
nopredictions can bemade about the pos-
sible effects of I-2 on tau pathology.
It must be noted that the results of Sun
et al. (2003) seem to contradict those of
Yang et al. (2015). Specifically, the com-
bined inhibition of PP1 and PP2A in the
study of Sun et al. (2003) resulted in a de-
crease of memory formation, whereas in
the study of Yang et al. (2015) “inhibi-
tion” of PP1 alone led to an increase in
learning and memory. These apparently
contradictory findings could potentially
be due to protective effects of PP2A on
learning and memory, as observed by
Zhang et al. (2014), which may outweigh
the inhibitory effects of PP1. Another pos-
sible explanation is that PP1 affects cogni-
tion via two different pathways with
opposing effects. Although PP1 reduces
learning and memory via inhibition of
CREB, it may slow AD pathology and re-
lieve cognitive impairments by decreasing
tau hyperphosphorylation (Fig. 1). Thus,
although decreasing PP1 activity by sup-
pressing I-2 is a potential therapeutic in-
tervention to increase memory function,
precautions should be taken, as a strong
decrease of PP1 activity might result in
faster progression of AD pathology.
As it stands, the connection between
PP1, I-2, AD, and tau hyperphosphoryla-
tion are unclear and warrant further in-
vestigation. To study the role of I-2 in the
pathophysiology of AD, experiments sim-
ilar to the one performed by Yang et al.
(2015) could be conducted in animal
models of tau pathology. Assuming that
I-2 is a PP1 stimulator, a decrease in I-2
could lead to more tau hyperphosphory-
lation, and therefore a faster progression
of AD pathology (Fig. 1).
In conclusion, the study of Yang et al.
(2015) showed that I-2 stimulates PP1 in
vivo. These findings are contrary to the
previous in vitro findings and thus offer a
new perspective on the endogenous func-
tion of I-2. Furthermore, I-2 likely acts as
a memory suppressor through PP1, by
stimulating dephosphorylation of CREB
and attenuating CREB-dependent gene
expression. Downregulating I-2 might
thus develop into a possible therapy for
cognitive impairments. One application
could be AD, as the progression of this
disease is associated with memory dys-
function. However, PP1 might affect the
pathophysiology of AD via anothermech-
anism, namely via the regulation of tau
hyperphosphorylation. Therefore, care
should be taken in attempting to alter PP1
activity through I-2, as it might accelerate
the progression of AD pathology and the
decline of memory functions. Future re-
search should address whether and how
the two proposed workingmechanisms of
PP1 are balanced, and assess whether I-2
can be used as a therapeutic agent without
increasing the risk for developing and
stimulating AD.
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